1. Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey.
- Author
-
Elkaddoum R, Zakhour J, Hajal M, Aoun M, Njeim M, Mahrous M, Al-Shamsi HO, Brahim ZB, Khatib SA, and Kourie HR
- Subjects
- Humans, Receptor Protein-Tyrosine Kinases genetics, Anaplastic Lymphoma Kinase genetics, Gene Rearrangement, Protein Kinase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Physicians
- Abstract
Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials & methods: A total of 118 physicians from 11 countries in the Middle East participated. Results & conclusion: Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).
- Published
- 2023
- Full Text
- View/download PDF